Handling Data Below the Limit of Quantification in Mixed Effect Models

No abstract is available for this paper.

• Publication year

  2009

• Venue

  AAPS Journal

• Publication date

  2009-05-19

• Fields of study

  Medicine, Computer Science, Environmental Science

• Identifiers
  DOI 10.1208/s12248-009-9112-5PMID 19452283PMCID PMC2691472
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Likelihood based approaches to handling data below the quantification limit using NONMEM VI

  2008cited by this paper
• Impact of censoring data below an arbitrary quantification limit on structural model misspecification

  2008cited by this paper
• Population Pharmacokinetics of Rifampin in Pulmonary Tuberculosis Patients, Including a Semimechanistic Model To Describe Variable Absorption

  2008cited by this paper
• PsN-Toolkit - A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM

  2005cited by this paper
• Erratum to "PsN-Toolkit - A collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM" [Comput. Methods Prog. Biomedicine 79 (2005) 241-257]

  2005cited by this paper
• The Visual Predictive Check Superiority to Standard Diagnostic (Rorschach) Plots

  2005cited by this paper
• Perl-speaks-NONMEM (PsN) - a Perl module for NONMEM related programming

  2004cited by this paper
• Impact of Omission or Replacement of Data Below the Limit of Quantification on Parameter Estimates in a Two-Compartment Model

  2002cited by this paper
• Ways to Fit a PK Model with Some Data Below the Quantification Limit

  2001cited by this paper
• Analysis of Toxicokinetic Data Using NONMEM: Impact of Quantification Limit and Replacement Strategies for Censored Data

  2001cited by this paper
• Xpose--an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM.

  1999cited by this paper
• Comparison of four basic models of indirect pharmacodynamic responses

  1993cited by this paper

• Population pharmacokinetics and dose-response relationships of mitoxantrone in children with acute myeloid leukaemia.

  2026cites this paper
• Developing tailored dosing recommendations for ciprofloxacin in critically ill children using a population approach based on total and unbound concentrations.

  2025cites this paper
• A semi-mechanistic pharmacokinetic/pharmacodynamic model for quantifying phage-antibiotic synergy against Pseudomonas aeruginosa

  2025cites this paper
• Population pharmacokinetics of TBAJ-587 and its main metabolites-Evaluation of different loading dose strategies and early dose selection.

  2025cites this paper
• Impact of Continuous Veno-Venous Hemodiafiltration on Thyroid Homeostasis in Critically Ill Patients

  2025cites this paper
• Population pharmacokinetics of artemether–lumefantrine plus amodiaquine in patients with uncomplicated Plasmodium falciparum malaria

  2025cites this paper
• The Reference-Corrected Visual Predictive Check: A More Intuitive Diagnostic for Non-Linear Mixed Effects Models

  2025cites this paper
• Target‐Mediated Modeling of Alirocumab in Adolescents and Children ≥8 to <12 Years of Age Using Phase II and III Data

  2025cites this paper
• A model-based comparison of dose reduction strategies for fixed-dose dolutegravir-containing regimens

  2025cites this paper
• Quantitative relationship between tominersen concentrations in cerebrospinal fluid and biomarker changes in Huntington's disease patients.

  2025cites this paper
• Population Pharmacokinetics of Intravenous Methadone Enantiomers in Adults: A Comprehensive Model

  2025cites this paper
• Enhancing Pharmacometric Modeling with Full Bayesian Inference and Student’s t-Based M3 Censoring: A Simulated Population PK Study on Robust Handling of Outliers and Censored Data

  2025cites this paper
• Population Pharmacokinetics Analysis of Talazoparib and Enzalutamide Combination Therapy for Patients With Metastatic Castration‐Resistant Prostate Cancer

  2025cites this paper
• Global research on the utilization of population pharmacokinetic model: a bibliometric analysis from 2000 to 2024

  2025cites this paper
• Population Pharmacokinetics and Exposure‐Response Relationship of Hemoporfin in Pediatric Patients With Port‐Wine Stain

  2025cites this paper
• A pharmacometric model assessing the in vitro synergistic effect of a bacteriophage-polymyxin B combination in a clinical multidrug-resistant K. pneumoniae isolate.

  2025cites this paper
• Population Cellular Kinetics of Idecabtagene Vicleucel in Patients with Triple-Class–Exposed Relapsed/Refractory Multiple Myeloma

  2025cites this paper
• A Pragmatic Approach to Handling Censored Data Below the Lower Limit of Quantification in Pharmacokinetic Modeling

  2025influential citation
• Population Pharmacokinetics of IV Lidocaine and its Metabolites in Adult Surgical Patients

  2025cites this paper
• Low Target Attainment of Intravenous Cefuroxime in Critically Ill Term Neonates and Children: A Pooled Population Pharmacokinetics Study

  2025cites this paper
• Population pharmacokinetics and pulmonary modeling of eravacycline and the determination of microbiological breakpoint and cutoff of PK/PD

  2025cites this paper
• Pharmacokinetic–Pharmacodynamic Cutoff Values for Doxycycline in Pigs to Support the Establishment of Clinical Breakpoints for Antimicrobial Susceptibility Testing

  2025cites this paper
• Application of population pharmacokinetic modeling of SVG-101 to evaluate proper dose selection

  2025cites this paper
• It Is Time to Re‐Think the Limit of Quantitation

  2025cites this paper
• Population pharmacokinetics of ritonavir as a booster of lopinavir, atazanavir, or darunavir in African children with HIV

  2025cites this paper
• Population Pharmacokinetic Modeling Analysis of ASC10, a Novel Antiviral Agent Targeted COVID-19, in Chinese Healthy Subjects

  2025cites this paper
• Time-Varying Clearance in Milrinone Pharmacokinetics from Premature Neonates to Adolescents

  2024cites this paper
• Population pharmacokinetics of intraperitoneal irinotecan and SN‐38 in patients with peritoneal metastases from colorectal origin

  2024cites this paper
• A sensitive GC–MS/MS method for the quantification of benzo[a]pyrene tetrol in urine

  2024cites this paper
• Five multivariate Duchenne muscular dystrophy progression models bridging six-minute walk distance and MRI relaxometry of leg muscles

  2024cites this paper
• Population Pharmacokinetics of Ledipasvir/Sofosbuvir in Pediatric Patients: Impact of Acute Lymphoblastic Leukemia.

  2024cites this paper
• Agreement Between a Colorimetric Assay and Ultra-Performance Liquid Chromatography-Tandem Mass Spectrometry for Quantifying Paracetamol Plasma Concentrations

  2024cites this paper
• Hypometric genetics: Improved power in genetic discovery by incorporating quality control flags.

  2024cites this paper
• Population pharmacokinetic–pharmacodynamic model of elinzanetant based on integrated clinical phase I and II data

  2024cites this paper
• Translational pharmacokinetic and pharmacodynamic modelling of the anti-ADAMTS-5 NANOBODY® (M6495) using the neo-epitope ARGS as a biomarker

  2024cites this paper
• Characterizing the Nonlinear Pharmacokinetics and Pharmacodynamics of BI 187004, an 11β‐Hydroxysteroid Dehydrogenase Type 1 Inhibitor, in Humans by a Target‐Mediated Drug Disposition Model

  2024cites this paper
• Increase in peg-asparaginase clearance as a predictor for inactivation in patients with acute lymphoblastic leukemia

  2024cites this paper
• Pharmacometrics to Evaluate Dosing of the Patient-Friendly Ivermectin CHILD-IVITAB in Children ≥ 15 kg and <15 kg

  2024cites this paper
• Socio-demographic inequalities influence differences in the chemical exposome among Swedish adolescents.

  2024cites this paper
• Disentangling Anti‐Tumor Response of Immunotherapy Combinations: A Physiologically Based Framework for V937 Oncolytic Virus and Pembrolizumab

  2024cites this paper
• Fentanyl dosage for preterm infants suggested by a pharmacokinetic, -dynamic, and -genetic model

  2024cites this paper
• Population Pharmacokinetics of Pegcetacoplan in Patients with Geographic Atrophy or Neovascular Age-related Macular Degeneration

  2024cites this paper
• Analyzing the worldwide progression of COVID-19 cases and deaths using nonlinear mixed-effects model

  2024cites this paper
• Tenofovir, emtricitabine, lamivudine and dolutegravir concentrations in plasma and urine following drug intake cessation in a randomized controlled directly observed pharmacokinetic trial to aid point-of-care testing

  2024cites this paper
• Trilaciclib dosage in Chinese patients with extensive-stage small cell lung cancer: a pooled pharmacometrics analysis

  2024cites this paper
• An In Vitro Study on the Role of Cellulases and Xylanases of Bacillus subtilis in Dairy Cattle Nutrition

  2024influential citation
• Does Sample Size, Sampling Strategy, or Handling of Concentrations Below the Lower Limit of Quantification Matter When Externally Evaluating Population Pharmacokinetic Models?

  2024cites this paper
• Assessment of body mass-related covariates for rifampicin pharmacokinetics in healthy Caucasian volunteers

  2024cites this paper
• Indirect modeling of derived outcomes: Are minor prediction discrepancies a cause for concern?

  2024cites this paper
• Comparative Analysis of Posiphen Pharmacokinetics across Different Species—Similar Absorption and Metabolism in Mouse, Rat, Dog and Human

  2024cites this paper
• A Pooled Population Pharmacokinetic Study of Oral and Intravenous Administration of Clavulanic Acid in Neonates and Infants: Targeting Effective Beta‐Lactamase Inhibition

  2024cites this paper
• A Model‐Informed Drug Development Approach to Design a Phase 3 Trial of Teverelix Drug Product in Advanced Prostate Cancer Patients with Increased Cardiovascular Risk

  2024cites this paper
• Clinical usefulness of a host signature based on TRAIL, IP10, and CRP (MeMed BV) as infection biomarkers in intensive care units' patients. A retrospective observational study.

  2024cites this paper
• The Impact of Continuous Veno-Venous Hemodiafiltration on the Efficacy of Administration of Prophylactic Doses of Enoxaparin: A Prospective Observational Study

  2023cites this paper
• Multivariate modeling of magnetic resonance biomarkers and clinical outcome measures for Duchenne muscular dystrophy clinical trials

  2023cites this paper
• Pharmacokinetic Interaction between Rifampicin and Clindamycin in Staphylococcal Osteoarticular Infections.

  2023cites this paper
• Exposure of Swedish adolescents to elements, persistent organic pollutants (POPs), and rapidly excreted substances - The Riksmaten adolescents 2016-17 national survey.

  2023cites this paper
• Model Based Estimation of Posaconazole Tablet and Suspension Bioavailability in Hospitalized Children Using Real-World Therapeutic Drug Monitoring Data in Patients Receiving Intravenous and Oral Dosing

  2023cites this paper
• Copanlisib population pharmacokinetics from phase I–III studies and exposure–response relationships in combination with rituximab

  2023cites this paper
• Low concentrations of perfluoroalkyl acids (PFAAs) in municipal drinking water associated with serum PFAA concentrations in Swedish adolescents.

  2023cites this paper
• Population Pharmacokinetic/Pharmacodynamic Analysis of the Glucokinase Activator PB201 in Healthy Volunteers and Patients with Type 2 Diabetes Mellitus: Facilitating the Clinical Development of PB201 in China

  2023cites this paper
• Semi-mechanistic modeling of resistance development to β-lactam and β-lactamase-inhibitor combinations

  2023cites this paper
• Population pharmacokinetic‐pharmacodynamic modeling of clopidogrel for dose regimen optimization based on CYP2C19 phenotypes: A proof of concept study

  2023cites this paper
• Evaluating pediatric tuberculosis dosing guidelines: A model-based individual data pooled analysis

  2023cites this paper
• Implementing best practices on data generation and reporting of Mycobacterium tuberculosis in vitro assays within the ERA4TB consortium.

  2023cites this paper
• Power to identify exposure‐response relationships in phase IIa pulmonary tuberculosis trials with multi‐dimensional bacterial load modeling

  2023cites this paper
• The importance of cellulolytic and xylanolytic activities of Bacillus subtilis on dairy cow feed digestibility

  2023cites this paper
• Developing a mechanistic translational PK/PD model for a trifunctional NK cell engager to predict the first‐in‐human dose for acute myeloid leukemia

  2023cites this paper
• Control of a Sulfadoxine/Trimethoprim Combination in the competition horse: Elimination, Metabolism and Detection following an intravenous Administration.

  2023cites this paper
• Semi-mechanistic population pharmacokinetic/pharmacodynamic modeling of a Plasmodium elongation factor 2 inhibitor cabamiquine for prevention and cure of malaria

  2023cites this paper
• Model based assessment of food and acid reducing agent effects on oral absorption of mezigdomide (CC‐92480), a novel cereblon E3 ligase modulator

  2023cites this paper
• Population pharmacokinetics of mirvetuximab soravtansine in patients with folate receptor‐α positive ovarian cancer: The antibody–drug conjugate, payload and metabolite

  2023cites this paper
• Are Ocular and Serum Half-Lives After Ranibizumab Intravitreal Injection Dependent on Dose?

  2023cites this paper
• A population pharmacokinetic model of methotrexate in Korean patients with haematologic malignancy

  2023cites this paper
• Pharmacokinetic properties of a new sustained-release pregabalin tablet in subjects with reduced renal function

  2023cites this paper
• Early bactericidal activity studies for pulmonary tuberculosis: a systematic review of methodological aspects.

  2023cites this paper
• Pharmacokinetic analysis across studies to drive knowledge‐integration: A tutorial on individual patient data meta‐analysis (IPDMA)

  2023cites this paper
• Association between tobacco exposure, blood pressure, and arterial stiffness in South African adults and children

  2022cites this paper
• Population pharmacokinetics of mobocertinib in healthy volunteers and patients with non–small cell lung cancer

  2022cites this paper
• Estimation of cefepime, piperacillin, and tazobactam clearance with iohexol-based glomerular filtration rate in paediatric patients

  2022cites this paper
• Healthy eating index and diet diversity score as determinants of serum perfluoroalkyl acid (PFAA) concentrations in a national survey of Swedish adolescents.

  2022cites this paper
• Target attainment of extended-interval dosing of tobramycin in patients less than five years of age with cystic fibrosis: A pharmacokinetic analysis.

  2022cites this paper
• Demographic, life-style and physiological determinants of serum per- and polyfluoroalkyl substance (PFAS) concentrations in a national cross-sectional survey of Swedish adolescents.

  2022cites this paper
• A Survey of Population Pharmacokinetic Reports Submitted to the USFDA: An Analysis of Common Issues in NDA and BLA from 2012 to 2021.

  2022cites this paper
• Dose optimization with population pharmacokinetics of ritonavir-boosted lopinavir for Thai people living with HIV with and without active tuberculosis.

  2022cites this paper
• Population pharmacokinetics of tanezumab following intravenous or subcutaneous administration to patients with osteoarthritis or chronic low back pain

  2022cites this paper
• Population Pharmacokinetics of Flucloxacillin In Bone and Soft Tissue– Standard Dosing is Not Sufficient to Achieve Therapeutic Concentrations

  2022cites this paper
• A comparison of statistical methods for animal oncology studies

  2022cites this paper
• Population PK and Semimechanistic PK/PD Modeling and Simulation of Relugolix Effects on Testosterone Suppression in Men with Prostate Cancer

  2022cites this paper
• Simultaneous monitoring of each component on degradation of blended bioplastic using gas chromatography-mass spectrometry.

  2022cites this paper
• Quantitative relationships of perfluoroalkyl acids in drinking water associated with serum concentrations above background in adults living near contamination hotspots in Sweden.

  2022cites this paper
• PKPD Modeling and Simulations to Support Biosimilar Development of Biphasic Insulin Aspart 30

  2022cites this paper
• Pharmacokinetic Modeling of Warfarin І – Model-Based Analysis of Warfarin Enantiomers with a Target Mediated Drug Disposition Model Reveals CYP2C9 Genotype-Dependent Drug-Drug Interactions of S-Warfarin

  2022cites this paper
• Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab

  2022cites this paper
• Pharmacokinetic Modeling of Warfarin ІI – Model-Based Analysis of Warfarin Metabolites after Warfarin Administered Either Alone or Together with Fluconazole or Rifampin

  2022cites this paper
• Population‐based cellular kinetic characterization of ciltacabtagene autoleucel in subjects with relapsed or refractory multiple myeloma

  2022cites this paper
• SARS-CoV-2-specific CD4+ T cells are associated with long-term persistence of neutralizing antibodies

  2022cites this paper
• Population Pharmacokinetics of Nifurtimox in Adult and Pediatric Patients With Chagas Disease

  2022cites this paper
• A Pharmacokinetic Analysis of Tobramycin in Patients Less than Five Years of Age with Cystic Fibrosis: Assessment of Target Attainment with Extended-Interval Dosing through Simulation

  2022cites this paper
• Population Pharmacokinetics of Intranasal Dexmedetomidine in Infants and Young Children

  2022cites this paper